What disease-modifying drugs are available for osteoarthritis in adults?

Disease-Modifying Anti-OA Drugs

There are currently no proven disease-modifying osteoarthritis drugs (DMOADs) available for clinical use in adults. Despite decades of research and numerous clinical trials investigating potential structure-modifying agents, no drug has demonstrated convincing evidence of altering the natural progression of osteoarthritis in a clinically meaningful way 1, 2.

What This Means for Clinical Practice

The absence of DMOADs fundamentally shapes how we approach OA treatment—we focus entirely on symptom management and functional improvement rather than disease modification. This is a critical distinction that patients need to understand: current treatments can help with pain and function, but cannot reverse or halt cartilage degradation.

Previously Investigated Agents (Not Recommended)

Glucosamine and Chondroitin

• NICE guidelines explicitly recommend against their use 1
• While older EULAR guidelines (2000-2003) suggested possible efficacy with effect sizes of 0.44-0.87 for glucosamine and 0.78 for chondroitin 3, these findings have not held up to modern scrutiny
• The 2019 ACR/Arthritis Foundation guideline made only a conditional recommendation for chondroitin sulfate in hand OA specifically 2, but this is based on limited evidence from a single well-performed trial
• For knee and hip OA, clinically meaningful effects have not been proven 4

Hyaluronic Acid (Intra-articular)

• NICE explicitly recommends against intra-articular hyaluronan injections 1
• Despite earlier EULAR data showing some pain reduction (effect sizes 0.04-0.9), the evidence for structure modification remains unconvincing 3, 5
• The benefit-to-risk ratio, including cost considerations and need for multiple injections, does not support routine use

Diacerein

• Limited evidence from single trials showing some symptomatic benefit 3
• Significant adverse events at higher doses
• Not recommended in current guidelines

The Current Research Landscape

What's Being Investigated

Recent research identifies several categories of potential DMOADs under investigation 6, 7, 8:

Repurposed drugs from other conditions:

• Drugs for osteoporosis (bisphosphonates)
• Diabetes medications (metformin, GLP-1 agonists)
• Cardiovascular drugs (statins)
• Anti-inflammatory agents from rheumatoid arthritis

Novel biological approaches:

• Mesenchymal stem cell therapy
• Platelet-rich plasma (PRP)
• Pro-anabolic agents targeting cartilage regeneration 7

Important caveat: Many of these show mixed results—some studies suggest disease-modifying effects while others show disease-aggravating effects, particularly for GLP-1 agonists, antihistamines, sex hormones, and statins 6.

Why This Matters for Patient Care

The Treatment Algorithm You Should Follow

Core treatments (always start here):

1. Exercise (strengthening and aerobic fitness)
2. Weight loss if BMI >25
3. Patient education and self-management programs 1, 2

Pharmacological symptom management (in order):

1. Paracetamol/acetaminophen for initial pain relief
2. Topical NSAIDs (especially for knee OA)
3. Oral NSAIDs with PPI (lowest effective dose, shortest duration)
4. Intra-articular corticosteroids for moderate-severe pain flares
5. Tramadol or duloxetine as alternatives 1, 2

Surgical intervention:

• Joint replacement when symptoms substantially affect quality of life and are refractory to non-surgical treatment 1

Common Pitfalls to Avoid

1. Don't prescribe glucosamine/chondroitin for knee or hip OA despite patient requests or older literature—the evidence doesn't support it 1

2. Don't use intra-articular hyaluronan despite its marketing as a "disease-modifying" treatment—NICE explicitly recommends against it 1

3. Don't promise patients that any current medication will "slow down" their arthritis—this sets false expectations and undermines trust when progression occurs

4. Don't delay core treatments (exercise, weight loss) while searching for a pharmaceutical solution—these non-pharmacological interventions have the strongest evidence base 2

The Bottom Line

The heterogeneous nature of OA and its multifactorial pathophysiology make DMOAD development exceptionally challenging 9. Until convincing evidence emerges from rigorous randomized controlled trials, focus on evidence-based symptom management and functional optimization rather than unproven structure-modifying claims. The most honest approach with patients is acknowledging this limitation while emphasizing the substantial benefits achievable through exercise, weight management, and appropriate analgesic strategies.